#### 1 Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins

#### 2 Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola

#### **3 Vaccine (rVSV**\[]\]**G-EBOV-GP**)

4 Vanessa Raabe<sup>1,2</sup>\*, Lilin Lai<sup>1</sup>, Juliet Morales<sup>1,3</sup>, Yongxian Xu<sup>1</sup>, Nadine Rouphael<sup>1</sup>, Richard T.

5 Davey<sup>4</sup>, Mark J. Mulligan<sup>1,2</sup>

6 \* Corresponding author

#### 7 Affiliations:

8 1 Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of

9 Medicine, School of Medicine, Emory University, 500 Irvin Court, Suite 200, Decatur, GA,

10 30030, USA

11 2 Present address: Division of Infectious Diseases & Immunology and NYU Langone Vaccine

12 Center, Department of Medicine, New York University Grossman School of Medicine,

- 13 Alexandria Center for Life Sciences West Tower, 3rd Floor, New York, NY, 10016, USA
- 14 3 Present address: Division of Global Disease Epidemiology and Control, Department of
- 15 International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street,
- 16 Baltimore, MD, 21205, USA
- 17 4 National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center
- 18 Drive, Rm. 4-1479, MSC 1460, Bethesda, MD 20892, USA
- 19 Author Email: Vanessa Raabe: <u>Vanessa.Raabe@nyulangone.org</u>; Yongxian Xu:
- 20 <u>y.xu@emory.edu;</u> Juliet Morales: jmoral22@jh.edu; Lilin Lai: <u>llai@emory.edu;</u> Nadine
- 21 Rouphael: <a href="mailto:nroupha@emory.edu">nroupha@emory.edu</a>; Richard T. Davey: <a href="mailto:rdavey@niaid.nih.gov">rdavey@niaid.nih.gov</a>; Mark J. Mulligan:
- 22 <u>Mark.Mulligan@nyulangone.org</u>
- 23

#### 24 Word Count: 4850

25 Abstract Word Count: 289

26

#### 27 Abstract

28 While effective at preventing Zaire ebolavirus (EBOV) disease, cellular immunity to EBOV and 29 vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing Ebola 30 glycoprotein (rVSV $\Delta$ G-EBOV-GP) vaccine remains poorly understood. Sera and peripheral 31 blood mononuclear cells were collected from 32 participants enrolled in a prospective 32 multicenter study [ClinicalTrials.gov NCT02788227] before vaccination and up to six months post-vaccination. IgM and IgG antibodies, IgG-producing memory B cells, and T cell reactivity 33 34 to EBOV glycoprotein, vesicular stomatitis virus-Indiana strain (VSV-I) matrix protein, and 35 VSV-I nucleoprotein were measured using ELISA, ELISpot, and intracellular cytokine staining, 36 respectively. Eleven participants previously received a different investigational Ebola vaccine. 37 All participants met positivity criteria for IgG antibodies to, and circulating IgG-producing 38 memory B cells to, EBOV glycoprotein following rVSVAG-EBOV-GP vaccination. Transient 39 IgM and IgG antibody responses to VSV-I matrix protein (n=1/32 and n=0/32, respectively) and 40 nucleoprotein (n=2/32 and n=1/32, respectively) were infrequently detected, as were IgG-41 producing memory B cells recognizing VSV-I matrix protein (n=3/31) and nucleoprotein 42 (n=2/31). CD4+ and CD8+ T cell responses to EBOV glycoprotein were present in 15/32 and 43 19/32 participants at baseline and in 32/32 and 23/32 participants one month post-vaccination, 44 respectively. CD4+ and CD8+ T cell responses to VSV-I matrix protein (n=17/32 and n=16/32,45 respectively) and VSV-I nucleoprotein (n=23/32 for both CD4+ and CD8+ responses) were 46 common post-vaccination. T cell responses were predominantly mono-cytokine, except CD8+

| 47 | responses to EBOV glycoprotein among heterologous Ebola vaccine-experienced participants      |
|----|---|
| 48 | and CD8+ responses to VSV-I nucleoprotein. Overall, rVSV $\Delta$ G-EBOV-GP elicits robust    |
| 49 | humoral and memory B cell responses to EBOV glycoprotein in both Ebola vaccine-naïve and      |
| 50 | heterologous Ebola vaccine-experienced individuals and can generate vector-directed T cell    |
| 51 | immunity. Further research is needed to understand the significance of pre-existing vector-   |
| 52 | directed immunity on responses to booster doses of rVSV $\Delta$ G-EBOV-GP and other rVSV-    |
| 53 | vectored vaccines.  |
| 54 |   |
| 55 | Keywords: Ebola Vaccine; Vesicular stomatitis-Indiana virus; Recombinant vaccines;            |
| 56 | Antibodies; T Cell; B cell  |
| 57 |   |
| 58 | Abbreviations: ChAd3-EBO-Z - replication-defective chimpanzee adenovirus 3 vector vaccine     |
| 59 | expressing Zaire ebolavirus glycoprotein; EBOV – Ebola virus; GP – glycoprotein; M – Matrix   |
| 60 | protein; MBC – Memory B cell; MVA-BN-Filo - modified vaccinia Ankara virus expression         |
| 61 | Zaire ebolavirus glycoprotein and other filovirus antigens; NP – Nucleoprotein; PREPARE - The |
| 62 | Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for       |
| 63 | Ebola-Zaire for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for    |
| 64 | Ebola Virus Exposure; rVSV- Recombinant vesicular stomatitis virus; rVSV $\Delta$ G-EBOV-GP – |
| 65 | Recombinant vesicular stomatitis virus Ebola vaccine; VSV-I – Vesicular stomatitis virus      |
| 66 | Indiana strain  |
| 67 |   |
| 68 | Funding: This work was supported by the National Institute of Allergy and Infectious Diseases |
| 69 | (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [grant  |

- number T32AI074492 to V.R, N.R., and M.J.M.] and NIH/NIAID contract number
- 71 HHSN272201300018I/HHSN27200021 to Emory University Vaccine and Treatment Evaluation
- 72 Unit. The content is solely the responsibility of the authors and does not necessarily represent the
- 73 official views of the National Institute of Allergy and Infectious Diseases or the National
- 74 Institutes of Health.
- 75
- 76 Competing Interests: MJM received research contracts from Lilly, Pfizer, and Sanofi, and
- serves on advisory boards for Pfizer and Meissa Vaccines. VR received a research contract from
- 78 Sanofi. NR received research contracts from Lilly, Pfizer, Merck, Quidel, and Sanofi.

#### 80 Introduction

81 Ebola virus disease is a continuing threat to human health since it was first identified in 1976, 82 notably causing large-scale outbreaks in West Africa from 2014-2016 involving over 28,000 83 cases and 11,325 deaths and in the Democratic Republic of Congo from 2018-2020 with over 84 3400 cases and 2200 deaths [1, 2]. These large-scale epidemics accelerated the development and 85 testing of Zaire ebolavirus (EBOV) vaccines, leading to European Medicines Agency and the 86 U.S. Food and Drug Administration approval of a recombinant vesicular stomatitis virus 87 expressing Ebola glycoprotein (rVSV∆G-EBOV-GP) vaccine in 2019 for the prevention of 88 disease due to Zaire ebolavirus [3, 4]. This vaccine utilizes a replication-competent vesicular 89 stomatitis virus – Indiana strain (VSV-I) from which the VSV-I glycoprotein (GP) gene has been 90 removed and replaced by the EBOV GP gene. The efficacy of the rVSVAG-EBOV-GP vaccine 91 for prevention of disease due to EBOV was estimated from a ring-vaccination study during an 92 Ebola outbreak to be 97.5% ten days or more post-vaccination and 88.1% at any time post-93 vaccination following administration of a single dose over a follow up period of approximately 94 11 months [5]. Ebola GP antibodies primarily mediate the protection conferred by the rVSV $\Delta$ G-95 EBOV-GP vaccine although the vaccine can elicit both CD4+ and CD8+ T cell responses to 96 EBOV GP [6, 7]. A combination of EBOV GP antibody titers  $\geq 200$  EU/mL plus a minimum 2-97 fold rise in EBOV GP antibody titers post-vaccination has been proposed as a vaccine-induced 98 seroresponse in humans, although a minimum antibody titer necessary to confer protection has 99 not been established [8]. CD4+ T cells play an important role in vaccine-induced antibody 100 development, but not in protection at the time of EBOV challenge, while CD8+ T cells may play 101 a minor role in protection [7, 9].

102

103 Knowledge gaps remain regarding cellular immunity to EBOV GP and vector-induced immunity 104 elicited by rVSV $\Delta$ G-EBOV-GP vaccination. Understanding vaccine vector-induced immunity is 105 important to assess for any unintended, potentially adverse consequences associated with use of 106 vectored vaccines in the setting of pre-existing vector immunity, such as modification of 107 vaccine-induced target antigen immunity or the potential to enhance susceptibility to infection, 108 as was observed among studies of adenovirus type 5 vectored HIV vaccine recipients [10-13], 109 but also to understand the potential for vector-induced immunity to limit target antigen immune 110 responses generated by subsequently administered vaccine doses utilizing the same vector. 111 Human infection with VSV-I is rare and the prevalence of naturally acquired VSV-I antibodies is 112 generally low with the exceptions of a few, geographically restricted regions [14]. The rVSV $\Delta G$ -113 EBOV-GP vaccine can elicit anti-VSV-I antibodies in non-human primates, although these did 114 not interfere with protection induced by a subsequently administered and similarly designed 115 recombinant vesicular stomatitis virus (rVSV) vaccine expressing Lassa virus GP [15]. In 116 retrospective analysis of a phase I clinical trial, transient, non-neutralizing antibodies directed 117 against the VSV-I matrix (M) protein and T cell responses against the VSV-I nucleoprotein (NP) 118 were elicited in a third of human rVSV $\Delta$ G-EBOV-GP vaccine recipients [16].

119

Expanding our understanding of immunity elicited by the rVSV $\Delta$ G-EBOV-GP vaccine against the target antigen and the VSV-I vector is critical for understanding the potential for long-term vaccine-induced protection against EBOV and the potential need for additional doses of rVSV $\Delta$ G-EBOV-GP vaccine, or future doses of other rVSV-based vaccines, to successfully initiate or boost immunity to the target antigen. Although the rVSV $\Delta$ G-EBOV-GP vaccine is currently approved as a single dose vaccine, the duration of protection following vaccination is

| 126 | unclear and clinical trials assessing the immunological benefit of booster doses of $rVSV\Delta G$ - |
|-----|--|
| 127 | EBOV-GP vaccination are underway [ClinicalTrials.gov NCT02788227, NCT02876328]. Here                 |
| 128 | we describe humoral, memory B cell, and T cell responses directed against Ebola GP, VSV-I M          |
| 129 | protein, and VSV-NP elicited in the first 6 months following rVSV $\Delta$ G-EBOV-GP vaccine         |
| 130 | administration from a subset of volunteers participating in an open-label, phase 2 clinical trial to |
| 131 | assess the durability of the immune response from rVSV $\Delta$ G-EBOV-GP. Additionally, we          |
| 132 | described differences in immune responses to the rVSV $\Delta$ G-EBOV-GP among individuals           |
| 133 | receiving an Ebola vaccine for the first time and those who previously received different Ebola      |
| 134 | vaccines.  |
| 135 |  |
| 136 | Materials and Methods  |
| 137 | Specimen Collection, Processing, and Storage: Additional blood specimens for this immunology         |
| 138 | substudy were obtained from a subset of participants enrolled in the PREPARE study                   |
| 139 | [ClinicalTrials.gov NCT02788227]. Study participants received the rVSVAG-EBOV-GP vaccine             |
| 140 | at their first study visit and were randomized at 18 months to a booster dose or no booster of the   |
| 141 | rVSV∆G-EBOV-GP vaccine. Written informed consent for the PREPARE study was obtained                  |
| 142 | from all participants, which permitted the study site to collect additional research specimens at    |
| 143 | scheduled study visits. The PREPARE study was approved by the US Food and Drug                       |
| 144 | Administration and the Emory University Institutional Review Board.                                  |
| 145 |  |
| 146 | Additional sera, plasma, and peripheral blood mononuclear cells (PBMCs) were collected at            |
| 147 | baseline, prior to $rVSV\Delta G$ -EBOV-GP vaccine administration, and one month, three months, and  |
| 148 | six months after initial rVSV $\Delta$ G-EBOV-GP vaccination. Serum samples were obtained using      |

| 149 | serum-separating tubes containing silica clot activator and polymer gel (BD, 367983) and were            |
|-----|--|
| 150 | processed by sitting at room temperature until clot formation was demonstrated followed by               |
| 151 | centrifugation. Plasma and PBMCs were obtained using CPT <sup>TM</sup> tubes with sodium heparin (BD     |
| 152 | #362753) following centrifugation. PBMCs were washed with phosphate-buffered saline (PBS),               |
| 153 | and cryopreserved in 90% fetal bovine serum (FBS) with 10% DMSO using a StrataCooler                     |
| 154 | (Agilent) at -80°C, after which PBMCs were stored in liquid nitrogen prior to use. All samples           |
| 155 | were processed within two hours of collection. Aliquots of sera and plasma were stored at -80 $^\circ$ C |
| 156 | until ready for initial use and additional aliquots that underwent one freeze-thaw cycle were            |
| 157 | subsequently stored at -20°C.  |
| 158 |  |
| 159 | ELISA: Antibodies to Ebola GP, VSV-I GP, VSV-I NP, and VSV-I M proteins were assessed by                 |
| 160 | indirect enzyme-linked immunosorbent assay (ELISA). Vesicular stomatitis virus GP is absent              |
| 161 | from the rVSV $\Delta$ G-EBOV-GP vaccine and served as a control for natural VSV-I infection during      |
| 162 | the study period. In brief, Nunc Maxisorb plates (Fisher #439454) were coated with 1 $\mu$ g/mL of       |
| 163 | recombinant Zaire ebolavirus glycoprotein minus trans-membrane region (IBT Bioservices                   |
| 164 | 0501-015), VSV-I glycoprotein (Mudd-Summers strain, MyBioSource MBS1060254), VSV-I                       |
| 165 | matrix protein (98COE North America strain, MyBioSource MBS1317470), or VSV-I                            |
| 166 | nucleoprotein (Glasgow strain, MyBioSource MBS1026155) diluted with PBS and incubated at                 |
| 167 | 4°C. Plates were blocked with PBS containing 0.05% Tween-20 (PBS-T), 5% dry milk, and 4%                 |
| 168 | whey for 1 hour, after which diluted serum was added in three-fold dilutions starting at 1:100           |
| 169 | and incubated at room temperature for 1 hours. Pooled serum from healthy volunteers                      |
| 170 | participating an influenza vaccine study served as a negative control and serum from an Ebola            |
| 171 | convalescent patient (provided courtesy of the Centers for Disease Control and Prevention),              |

| 172 | murine anti-VSV glycoprotein antibodies (Sigma-Aldrich V5507) diluted 1:2000, murine anti-        |
|-----|---|
| 173 | VSV matrix antibodies (Kerafast EB0011) diluted 1:2000, and murine anti-VSV nucleoprotein         |
| 174 | antibodies (Kerafast EB0009) diluted 1:2000 were used as positive controls. Plates were washed    |
| 175 | with PBS-T and incubated with horseradish peroxidase (HRP) goat anti-human IgG antibody           |
| 176 | (Jackson ImmunoResearch #109-036-098) diluted 1:10000, HRP goat anti-mouse IgG Fc                 |
| 177 | (ThermoFisher A16084) diluted 1:20000, or HRP goat anti-human IgM antibody (Jackson               |
| 178 | ImmunoResearch #109-035-129) diluted 1:20000 for 1 hour. KPL SureBlue TM TMB                      |
| 179 | Microwell Peroxidase Substrate (KPL 52-00-00) was added for 5 minutes, the reaction was           |
| 180 | stopped with 1N hydrochloric acid (VWR #BDH3202-2), and optical densities at 450 nm were          |
| 181 | read using a Biotek EL808 ELISA plate reader at room temperature. All samples were run in         |
| 182 | duplicate. We defined a positive antibody response to VSV-I proteins by an optical density (OD)   |
| 183 | at 450 nm at 1:100 dilution at least three standard deviations above the mean OD of all           |
| 184 | individuals at baseline and for Ebola glycoprotein, by an OD at 450 nm at 1:100 dilution at least |
| 185 | three standard deviations above the mean OD of vaccine-naïve individuals at baseline.             |
| 186 |   |
| 187 | PBMC Thawing: Cryopreserved PBMCs were thawed in R10 containing DNase I (Roche                    |
| 188 | #04716728001), washed, and resuspended in R10 with DNase I. Cell counting and viability           |

assessment was performed using a Guava easyCyte counter (Luminex) per the manufacturer

190 instructions. For intracellular cytokine staining, freshly thawed cells were rested overnight at an

incubator at 37°C with 5% carbon dioxide and repeat counting and viability assessment wereperformed prior to use.

193

194 IgG-producing Memory B Cell ELISpot: IgG-producing memory B cell (MBC) ELISpots were 195 performed using recombinant Zaire ebolavirus glycoprotein minus trans-membrane region, VSV-196 I matrix protein, and VSV-I nucleoprotein on PBMCs at baseline and 6 months post-vaccination. 197 In brief, cryopreserved PBMCs were thawed, stimulated with B-poly-S containing IL-2 and 198 R848 (Cellular Technology Limited CTL-hBPOLYS-200) and 2-mercaptoethanol (Sigma-199 Aldrich M3148) in a 24 well flat-bottom cell culture plate (Fisher Scientific 07-200-740), and 200 incubated for 5 days at 37°C. 96-well multiscreen-HA plates (Millipore MSHAN4B50) were 201 coated with 2.5 µg/mL EBOV-GP, 2 µg/mL of VSV-I M protein, VSV-I NP, or donkey anti-202 human IgG (Jackson Immuno Research Laboratory 709-005-149) and stored at 4°C for 1-7 days 203 prior to use. On day 6, plates were washed with PBS-T and blocked with RPMI 1640 with L-204 glutamine and HEPES (Fisher MT10041CV) with 10% fetal bovine serum (Hyclone 205 SH30088.03) and penicillin and streptomycin solution (Cellgro 30-002-CI). Three-fold dilutions 206 of PBMCs were added to the 96-well plates starting at 1:3 dilution for viral antigen wells and 207 1:30 dilution for anti-human IgG wells and incubated for 6 hours at 37°C. Plates were washed 208 with PBS and PBS-T, and incubated overnight at 4°C with biotin-conjugated donkey anti-human 209 IgG Fc antibody (Jackson Immuno Research Laboratory 709065098). After washing with PBS-210 T, samples were incubated with Avidin D conjugated with HRP (Vector Laboratories A-2004) 211 for 1 hour at room temperature, plates were washed with PBS-T and PBS. 3-amino-9-212 ethylcarbazole substrate (Sigma A-5754) was added for 5 minutes and plates were washed with 213 water and allowed to dry in the dark prior to being analyzed with an Immunospot S6 Universal 214 Analyzer (Cellular Technology Limited). All samples were run in duplicate. To account for 215 differences in the quantity of IgG-producing memory B cells present per million PBMCs, the 216 number of antigen-specific spots per million PBMCs was divided by the total number of IgG-

| 217 | producing spots per million PBMCs and multiplied by 100 to produce an antigen-specific/total                     |
|-----|--|
| 218 | IgG-producing memory B cell percentage. An antigen-specific/total IgG-memory B cell                              |
| 219 | percentage of $\geq 0.10\%$ was considered a positive test.  |
| 220 |  |
| 221 | Intracellular Cytokine Staining: Intracellular cytokine staining of PBMCs collected at baseline                  |
| 222 | and one month post-vaccination were assessed for production of interferon $\gamma$ (IFN- $\gamma$ ), interleukin |
| 223 | 2 (IL-2), and tumor necrosis factor $\alpha$ (TNF- $\alpha$ ) from T cells stimulated with peptide pools         |
| 224 | spanning the Zaire ebolavirus GP (Mayinga strain, JPT PM-ZEBOV-GPMay), VSV-I M protein,                          |
| 225 | or VSV-I NP. Peptides sequences to match the recombinant VSV-I M (MyBioSource                                    |
| 226 | MBS1317470) and NP (MyBioSource MBS1026155) antigens used for ELISA and ELISpot                                  |
| 227 | assays were custom prepared by Genscript as 15-mer peptides with 10-mer overlaps sequence                        |
| 228 | and pooled to create a concentration of 200 $\mu$ g/mL. Stimulated cells without antigen and                     |
| 229 | staphylococcal enterotoxin B (Sigma-Aldrich S4881) served as negative and positive controls.                     |
| 230 |  |
| 231 | In brief, cryopreserved PBMCs were thawed and rested overnight as above. Cells were incubated                    |
| 232 | with antigen-specific peptide pools, CD28 (BD #555725), and CD49d (BD #555501) for 6 hours                       |
| 233 | at 37°C; brefeldin A and monensin (eBioscience #5537) were added after 2 hours of incubation.                    |
| 234 | Cells were washed, stained with viability dye (Zombie Aqua, Biolegend #L423101), and                             |
| 235 | fixated/permeabilized using Cytofix/Cytoperm (BD, #554722). Staining was performed using                         |
| 236 | fluorescent-conjugated antibodies to CD3 (SP34-2, #562877), CD4 (L200, #560836), CD8                             |
| 237 | (RPA-T8, #555367), IL-2 (MQ1-17H12, #554567), and TNF-α (Mab11, #560679) from BD                                 |
| 238 | Bioscience and IFN- $\gamma$ (4S.B3, #47731942) from eBioscience. Flow cytometry was performed on                |
|     |  |

a LSRII (BD Bioscience) and data analysis was performed using FlowJo. A positive antigenspecific T cell response was defined as ≥ 0.01% of T cells producing at least one cytokine and ≥
2-fold antigen-specific production of the same cytokine compared to the same visit negative
control.

243

244 **Results** 

245 Blood samples were obtained from thirty-two participants enrolled in the PREPARE study.

246 Samples were obtained at baseline prior to rVSVAG-EBOV-GP vaccine administration, one

247 month post-vaccination, and three months post-vaccination for all 32 participants and at six

248 months post-vaccination for thirty-one participants. The median age of participants was 40 years

(age range: 24 - 67 years) and 11/32 (34.3%) had previously received at least one heterologous


250 investigational Ebola vaccine, either a replication-defective chimpanzee adenovirus 3 vector

251 vaccine expressing Zaire Ebolavirus glycoprotein (ChAd3-EBO-Z) alone or ChAd3-EBO-Z

followed by a modified vaccinia Ankara virus expression EBOV glycoprotein and other filovirus

antigens (MVA-BN-Filo) [Table 1].

254



| 261 | (mean OD 0.847 to 0.153; Figure 1B). Ebola GP IgG ODs rose following vaccination in all but       |
|-----|---|
| 262 | one Ebola vaccine-experienced participant who had a very high baseline Ebola GP IgG OD of         |
| 263 | 3.05. Lower Ebola GP IgG OD values were observed among all participants ages 20-29                |
| 264 | compared to older participants at all time points (baseline: p=0.026, 1 month: p=0.003, 3 months: |
| 265 | p<0.001, 6 months: p<0.001) although no differences in OD values were observed when the           |
| 266 | analysis was restricted only to participants who were vaccine-naïve at study entry (baseline:     |
| 267 | p=0.89, 1 month: p=0.89, 3 months: p=0.95, 6 months: p=0.91).                                     |
| 268 |   |
| 269 | IgM antibodies to EBOV GP were positive (OD $\ge$ 0.127 at 1:100 dilution) in 18/32 (56.3%) of    |

270 participants one month post-rVSVAG-EBOV-GP vaccination, 8/32 (25%) participants three

271 months post-vaccination, and 6/31 (19.4%) at six months post-vaccination (Figure 1C). At

272 baseline, no difference was observed between mean EBOV GP IgM ODs in Ebola vaccine-

273 naïve) versus experienced participants (mean OD 0.078 vs 0.075; p=0.10, Figure 1D). Positive

Ebola GP IgM ODs were observed only among Ebola vaccine-naïve participants and did not

275 differ based on age or gender (data not shown). Among Ebola vaccine-naïve participants at

enrollment, IgM responses were observed in 85.7%, 38.1%, and 28.6% at one month, three

277 months, and six months post-vaccination, respectively.

278

No participants developed IgG antibodies to VSV-I M protein ( $OD \ge 2.773$  at 1:100 dilution; Figure 2A). One participant had IgM antibodies to VSV-I M protein ( $OD \ge 0.173$  at 1:100 dilution) detectable up to 3 months post-vaccination and one participant had an isolated, positive IgM VSV-I M protein level at baseline (Figure 2B). One participant developed a transient IgG


responses to VSV-I NP (OD  $\geq$  2.359 at 1:100 dilution) at one month post-vaccination (Figure 284 2C). Two participants developed an IgM response to VSV-I NP (OD  $\geq$  0.297 at 1:100 dilution) 285 one month post-vaccination while one participant had positive IgM antibodies to VSV-I NP 286 detected only at baseline (Figure 2D). No participant developed IgG responses (OD  $\geq$  1.584) to 287 VSV-I GP during the study period (Figure 2E).

288

289 IgG-Producing MBCs: At baseline, 6 participants (19.4%), all of whom were Ebola-vaccine 290 experienced, had detectable IgG-producing MBCs to EBOV GP while 31/31 (100%) had 291 detectable EBOV GP antigen-specific IgG-producing MBCs at six months post-vaccination 292 (Figure 3A; 3B). The percentage of EBOV GP specific MBCs was only weakly correlated with 293 EBOV GP IgG ODs at 6 months post-vaccination (r=0.06). At baseline, 2 participants (6.5%) 294 and 4 participants (12.9%) had detectable IgG-producing MBC responses to VSV-I NP and 295 VSV-I M protein, respectively. Among participants positive for IgG-producing memory B cells 296 to VSV-I antigens at baseline, VSV-I specific IgG-producing MBCs were no longer detectable at 297 six months post-vaccination in all except one participant (3.2%) who had baseline detectable 298 IgG-producing MBC responses to VSV-I M. Post-vaccination, two participants (6.5%) 299 developed new IgG-producing MBC responses to VSV-I NP, both of whom also developed new 300 IgG-producing MBC responses to VSV-I M protein (Figure 3C). One participant (3.2%) 301 developed a new IgG-producing MBC response to VSV-I M protein post-vaccination, but not to 302 VSV-I NP. None of the three participants with new IgG-producing MBC responses to VSV-I 303 antigens post-vaccination had detectable serum antibodies to VSV-I M protein or NP following 304 vaccination. IgG-producing MBC responses to VSV-I proteins were of a lower magnitude (0-

| 305 | 0.20% antigen-specific/total IgG-producing MBCs) compared to the IgG-producing MBC   |
|-----|--|
| 306 | response elicited by EBOV GP (0.11-2.68% antigen-specific/total IgG-producing MBCs). |
| 307 |  |

| 308 | Intracellular Cytokine Staining: Positive CD4+ T cell responses following stimulation of             |
|-----|--|
| 309 | PBMCs with peptides spanning the full-length EBOV GP were observed in 15 participants                |
| 310 | (46.9%, 9 Ebola vaccine-experienced, 6 Ebola vaccine-naïve) at baseline and 100% of                  |
| 311 | participants one month post-vaccination. A significant increase in the mean percentage of CD4+       |
| 312 | T cells producing IFN-γ post-vaccination was observed among Ebola vaccine-naïve participants         |
| 313 | (p=0.002) while Ebola vaccine-experienced participants experienced a significant increase            |
| 314 | (p=0.04) in the mean percentage of CD4+ T cells producing IL-2 (Figure 4A). Mean percentages         |
| 315 | of CD4+ T cells producing IL-2 and TNF- $\alpha$ upon stimulation with EBOV GP peptides were not     |
| 316 | different between Ebola vaccine-naïve and vaccine-experienced individuals at baseline or post-       |
| 317 | vaccination, while Ebola vaccine-experienced participants had higher mean percentages of CD4+        |
| 318 | T cells producing IFN- $\gamma$ than Ebola vaccine-naïve participants at baseline (0.020% to 0.004%, |
| 319 | p=0.009) and but not one month post-vaccination (0.033% to 0.018%, p=0.05).                          |
| 320 |  |



327 EBOV GP peptides at baseline compared to vaccine-naïve participants (0.019% to 0.003%,

328 p=0.001), otherwise no significant differences in the mean percentage of cytokine-producing

329 CD8+ cells upon EBOV GP peptide stimulation were observed between Ebola vaccine-

330 experienced and vaccine-naïve participants.

331

332 Stimulation with peptides spanning the VSV-I matrix protein led to significant increases in IFN-

333  $\gamma$ , IL-2, and TNF- $\alpha$  from both CD4+ T cells (IFN- $\gamma$ : 0.22% to 0.67%; p=0.003; IL-2: 0.57% to

334 2.78%, p<0.001; TNF-α: 2.78% to 7.07%, p<0.001; Figure 4C) and CD8+ T cells (IFN-γ: 0.19%

335 to 1.35%; p=0.009; IL-2: 0.26% to 1.08%, p=0.03; TNF-α: 0.59% to 1.37%, p=0.02; Figure 4D).

336 Positive CD4+ and CD8+ T cell cytokine responses to VSV-I M protein were present in 2/32


337 (6.3%) and 6/32 (18.8%) of participants at baseline and 17/32 (53.1%) and 16/32 (50%) of

338 participants at 6 months post-vaccination, respectively. Baseline T cell reactivity to VSV-I M

protein was not associated with differences in the fold-change of Ebola GP IgG ODs at 1 month

340 compared to baseline (Figure 5A, CD4+ T cells: p=0.71; CD8+ T cells: p=0.33).

341



343 from CD4+ T cells (IFN-γ: 0.21% to 1.16%; p=0.001; IL-2: 0.55% to 4.35%, p<0.001; TNF-α:

344 2.02% to 8.01%, p<0.001; Figure 4E) and CD8+ T cells (IFN-γ: 0.21% to 0.57%; p=0.004; IL-2:

0.28% to 2.42%, p=0.01; TNF-α: 0.66% to 4.69%, p=0.047; Figure 4F). Positive CD4+ and

346 CD8+ T cell cytokine responses to VSV-I NP were present in 4/32 (12.5%) and 6/32 (18.8%) of

347 participants at baseline and 23/32 (71.9%) and 21/32 (71.9%) of participants at 6 months post-

348 vaccination, respectively. Neither baseline CD4+ or CD8+ reactivity to VSV-I NP were

| 349 | associated with differences in the fold-change of EBOV GP IgG ODs at 1 month compared to         |
|-----|--|
| 350 | baseline (Figure 5B, CD4+ T cells: p=0.10; CD8+ T cells: p=0.16).                                |
| 351 |  |
| 352 | Post-vaccination CD4+ T cell responses to EBOV GP peptides were primarily mono-cytokine,         |
| 353 | while CD8+ T cell responses were predominantly mono-cytokine for Ebola vaccine-naïve             |
| 354 | participants and polyfunctional for heterologous Ebola vaccine-experienced participants (Figures |
| 355 | 6A-D). Cellular responses to VSV-I Matrix protein were predominantly mono-cytokine for both      |
| 356 | CD4+ and CD8+ T cells (Figures 6E, 6F). CD4+ T cell responses to VSV-I NP were                   |
| 357 | predominantly mono-cytokine while most CD8+ T cellular responses were polyfunctional             |
| 358 | (Figures 6G, 6H).  |
|     |  |

359

### 360 Discussion

361 Among the 32 participants in this study, all met our definition for a positive Ebola GP IgG 362 response by three months post-rVSVAG-EBOV-GP vaccination, including 4 heterologous Ebola 363 vaccine-experienced individuals who did not meet positivity criteria at baseline. To our 364 knowledge, this is the first study to describe the use of the rVSV∆G-EBOV-GP vaccine among 365 prior heterologous Ebola vaccine recipients. Notably, the rVSVAG-EBOV-GP vaccine induced 366 increased EBOV GP IgG ODs in the majority of vaccine-experienced recipients, raising the 367 potential for the rVSVAG-EBOV-GP vaccine to be used as a booster for recipients of 368 heterologous Ebola vaccines with waning immunity. Failure to increase Ebola IgG OD on 369 ELISA following rVSVAG-EBOV-GP vaccine administration only occurred in a single 370 heterologous Ebola vaccine-experienced individual who exhibited high baseline ODs for EBOV

371 GP IgG antibodies well above the study-defined positivity threshold. Among participants in a 372 previous clinical trial that administered two doses of rVSVAG-EBOV-GP vaccine twenty-eight 373 days apart, only 12% of participants had detectable plasma rVSV $\Delta$ G-EBOV-GP virus three days 374 after the second dose of vaccination, compared to 95% after the first dose, suggesting vaccine-375 induced immunity inhibits the ability of the vaccine virus to replicate with subsequent doses 376 [17]. We hypothesize the high baseline level of pre-existing EBOV GP IgG antibodies in the 377 participant whose Ebola GP IgG OD did not increase post-rVSVAG-EBOV-GP vaccination were 378 responsible for neutralizing the vaccine virus prior to the establishment of successful rVSV $\Delta$ G-379 EBOV-GP virus infection in this individual, however since the PREPARE protocol did not 380 include early post-vaccination time points, we cannot definitively assess whether this is the case. 381 The failure of this individual to respond to the rVSV $\Delta$ G-EBOV-GP vaccine suggests further 382 research is needed to understand the role of pre-existing EBOV GP IgG antibodies and their 383 potential interference with the rVSVAG-EBOV-GP vaccine to understand which populations are 384 most likely to benefit from booster doses of rVSV $\Delta$ G-EBOV-GP. 385

386 IgM antibodies to EBOV GP generated by the rVSVAG-EBOV-GP vaccine have been 387 demonstrated to provide up to 50% of antibody-mediated neutralization of EBOV, and therefore 388 may contribute to early vaccine-mediated protection from disease [18]. IgM antibodies to EBOV 389 GP were detectable only among participants who were Ebola vaccine-naïve prior to 390 administration of the rVSVAG-EBOV-GP vaccine. In contrast, IgM was the primary antibody 391 type identified four weeks following two doses of rVSVAG-EBOV-GP vaccine given twenty-392 eight days apart [18]. The differences in the observed results could be due to longer durations 393 between Ebola vaccine doses among Ebola vaccine-experienced participants in this study or the

| 394 | type of Ebola vaccine used as the priming dose. Alternatively, it is possible that heterologous      |
|-----|--|
| 395 | Ebola vaccine-experienced participants in this study mounted transient IgM antibody responses        |
| 396 | to rVSV $\Delta$ G-EBOV-GP vaccine that resolved prior to the first post-vaccination visit one month |
| 397 | later. Among Ebola naïve participants at baseline, IgM positivity declined after the one month       |
| 398 | visit, but was still detectable in nearly one-fifth of participants at six months post-vaccination.  |
| 399 | Prolonged EBOV GP IgM positivity following rVSVAG-EBOV-GP vaccination have been noted                |
| 400 | in other studies, therefore caution should be used when interpreting diagnostic tests for EBOV       |
| 401 | that include EBOV GP IgM antibodies among rVSV $\Delta$ G-EBOV-GP vaccinees [18, 19].                |
| 402 |  |
| 403 | While the duration of protection against EBOV conferred by the rVSV $\Delta$ G-EBOV-GP vaccine       |
| 404 | remains unclear, we demonstrated that the VSV $\Delta$ G-EBOV-GP vaccine generates B cell memory     |
| 405 | to EBOV GP. All participants had detectable, circulating IgG-producing memory B cells                |
| 406 | recognizing EBOV GP following vaccination. Whether this immunological memory will be                 |
| 407 | sufficient to provide complete protection against EBOV disease in the setting of waning serum        |
| 408 | antibody levels over time has yet to be determined.  |
| 409 |  |

Vaccine vector-directed humoral immune responses to the VSV-I matrix protein and
nucleoprotein were uncommon among vaccine recipients. No participants developed IgG
antibodies directed at the VSV-I matrix protein, in contrast to 28% of rVSV∆G-EBOV-GP
vaccinees with detectable, although transient, IgG antibodies by Poetsch et al [16], and only one
participant developed transient IgG antibodies to the VSV-I nucleoprotein. Likewise, detectable
IgG-producing memory B cells to VSV-I proteins were low. Taken together, our data indicate

| 416 | that most rVSV $\Delta$ G-EBOV-GP vaccinees do not acquire humoral immunity to viral vector         |
|-----|---|
| 417 | proteins after one dose of rVSV $\Delta$ G-EBOV-GP vaccine. Antibodies to VSV-I matrix protein      |
| 418 | induced by the rVSVAG-EBOV-GP vaccine have been shown to be non-neutralizing in vitro, but          |
| 419 | the neutralizing capacity of VSV-I nucleoprotein antibodies in humans has not been assessed to      |
| 420 | our knowledge [16]. In a non-human primate model, antibodies to whole VSV were induced by a         |
| 421 | rVSV vaccine expressing EBOV GP, but did not impair protection from a subsequently given            |
| 422 | rVSV vaccine expressing Lassa virus GP, although only three primates were challenged [15].          |
| 423 | Whether or not anti-VSV antibodies negatively impair responses to booster doses of rVSV $\Delta$ G- |
| 424 | EBOV-GP vaccine, or future doses other replication-competent, rVSV-based vaccines, in               |
| 425 | humans remains to be determined.  |

426

427 Similar to previous studies, we found the rVSVAG-EBOV-GP vaccine can elicit CD4+ and 428 CD8+ T cells to EBOV GP producing IFN-γ and IL-2 [6]. Production of IFN-γ and IL-2 T cell 429 responses to EBOV GP may be associated with the development of symptoms such as 430 arthralgias, fatigue, headache, and myalgias following rVSV $\Delta$ G-EBOV-GP vaccination [20]. In 431 this study, the cytokine profile produced by T cells differed between Ebola vaccine-experienced 432 and vaccine-naïve individuals. EBOV GP CD8+ T cell responses to EBOV GP were more 433 polyfunctional in nature in this study compared to those documented by Dahlke et al., especially 434 among heterologous Ebola vaccine-experienced participants [6]. Interestingly, some of the Ebola 435 vaccine-naïve individuals met our criteria for detectable T cell responses to EBOV GP peptides 436 prior to vaccination, which may represents non-specific epitope cross-reactivity in the setting of 437 seronegativity to EBOV GP. Cytokine production from CD8+ T cells stimulated with EBOV GP 438 peptide pools prior to rVSV $\Delta$ G-EBOV-GP vaccination was also observed in some participants

| 439 | studied by Dahlke et al. [6]. Although we cannot rule out immunological interference between       |
|-----|--|
| 440 | pre-existing T cells recognizing EBOV GP with vaccine-induced EBOV GP antibody responses,          |
| 441 | we suspect these do not cause clinically significant interference with the rVSV $\Delta$ G-EBOV-GP |
| 442 | vaccine-induced target antigen humoral response given 100% of participants in this study met       |
| 443 | our criteria for a positive EBOV GP IgG response by 3 months post-vaccination despite 46.9%        |
| 444 | and 59.4% of participants having CD4+ and CD8+ T cells, respectively, capable of producing         |
| 445 | cytokines in response to EBOV GP peptide pools at baseline.  |
|     |  |

446

447 T cell responses to peptides from VSV-I proteins were uncommon at baseline among 448 participants, but were relatively common at one month post-vaccination, particularly to the VSV-449 I nucleoprotein. The VSV-I nucleoprotein is the most common target for CD8+ T cell responses 450 in mice infected with VSV-I [21], although no data exists on cellular immunity in humans 451 infected with VSV-I to our knowledge. The proportion of participants with CD8+ T cell 452 responses to VSV-I NP peptides in this study, 71.9%, is higher than that reported in a 453 retrospective analysis of a phase I rVSVAG-EBOV-GP clinical trial using three different vaccine 454 doses, in which 36% of vaccinees demonstrated CD8+ T cell responses to VSV-I nucleoprotein 455 [16]. Interestingly, we observed more polyfunctional VSV-I nucleoprotein-specific CD4+ and 456 CD8+ T cells in our study than had previously been reported following vaccination, where 457 predominantly mono-cytokine production of TNF- $\alpha$  was observed [16]. These vector-directed T 458 cell responses potentially could negatively affect the immune response to booster doses to rVSV-459 based vaccines. We did not see differences in the fold-change of the Ebola GP IgG optical 460 density at 1 month post-vaccination between the participants in this study with and without T 461 cells responses to VSV-I proteins at baseline, however, this should be interpreted cautiously in

the setting of the small number of participants with baseline T cell recognition of VSV-I proteins. The main PREPARE trial itself, from which our immunology substudy is derived, provides an opportunity to assess the impact of the vector-directed immune responses elicited by the rVSV $\Delta$ G-EBOV-GP vaccine on the response to future doses, as participants are randomized to receive or not receive a booster dose of rVSV $\Delta$ G-EBOV-GP vaccine eighteen months after the original dose.

468

469 Limitations of the study include the small number of participants assessed, especially of 470 heterologous Ebola vaccine-experienced individuals. The Ebola vaccine-experienced individuals 471 had previously received vaccine constructs other than the rVSV $\Delta$ G-EBOV-GP vaccine, 472 therefore, the immune responses among Ebola vaccine-experienced individuals reported in this 473 study may not be reflective of vaccine responses provided by homologous prime and boost with 474 the rVSVAG-EBOV-GP vaccine. No early time points prior to one month post-vaccination were 475 scheduled in the parent study to assess whether pre-existing EBOV GP IgG antibodies among 476 Ebola vaccine-experienced participants altered the course of rVSV $\Delta$ G-EBOV-GP vaccine 477 viremia or the development of a circulating follicular helper T cell response post-vaccination, 478 which correlates with EBOV GP antibody titers 4 weeks after vaccination [22]; important areas 479 for future research to determine who may be most likely to benefit from rVSVAG-EBOV-GP 480 vaccine booster doses. Given the lack of data on immunity to VSV-I infection in humans and the 481 absence of meaningful cut-offs for antibody titers, we presented data in optical density format to 482 be comparable with previously reported studies and selected our lowest ELISA dilution as the 483 most comprehensive for analysis, although we suspect the wide distribution of IgG ODs to all

- 484 VSV-I proteins at baseline by ELISA indicates non-specific antigen cross-reactivity with non-
- 485 VSV-I antibodies, which has previously been reported [23].

486

- 487 In conclusion, the rVSVAG-EBOV-GP vaccine frequently elicits EBOV-GP-specific IgG
- 488 antibody and IgG-producing memory B cell responses, and CD4+ and CD8+ T cell responses to
- 489 EBOV GP in both Ebola vaccine-naïve and experienced individuals. T cell responses to VSV-I
- 490 proteins are commonly elicited by rVSVAG-EBOV-GP, although vaccine vector-directed
- 491 humoral and IgG-producing memory B cell responses are rare. Additional research is needed to
- 492 understand the implications of vaccine-elicited immunity, both to the vector and to target
- 493 antigens, on the immune response to booster doses of the rVSV $\Delta$ G-EBOV-GP vaccine.

# 495 **Tables**

|                                      | Number of Participants (%) |
|--------------------------------------|----------------------------|
|                                      | N= 32                      |
| Gender                               |                            |
| Female                               | 17 (53.1%)                 |
| Male                                 | 15 (46.9%)                 |
| Age (years)                          |                            |
| 20-29                                | 3 (9.4%)                   |
| 30-39                                | 13 (40.6%)                 |
| 40-49                                | 11 (34.4%)                 |
| 50-69                                | 3 (9.4%)                   |
| $\geq 60$                            | 2 (6.3%)                   |
| Baseline Ebola Vaccine Status        |                            |
| Naïve                                | 21 (65.6%)                 |
| ChAd3-EBO-Z only                     | 2 (6.3%)                   |
| ChAd3-EBO-Z with MVA-BN-Filo booster | 9 (28.1%)                  |

## 496 Table 1: Demographics of Study Participants

497 ChAd3-EBO-Z: replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire

498 ebolavirus glycoprotein. MVA-BN-Filo: modified vaccinia Ankara virus expressing Zaire

499 ebolavirus glycoprotein and other filovirus antigens (glycoproteins from Marburg virus, Sudan

500 virus, and Tai Forest virus).

#### 502 Figure Legends

- 503 Figure 1: Antibody responses to Zaire ebolavirus glycoprotein by ELISA
- 504 Baseline vaccine-experienced participants are shown in grey and vaccine-naïve participants are
- shown in green. A: EBOV GP IgG antibody optical densities at 1:100 dilution for each
- 506 participant from baseline prior to rVSV∆G-EBOV-GP vaccination and one, three, and six
- 507 months post-vaccination. The positive OD threshold is indicated by a dashed line. B: EBOV GP
- 508 IgG antibody optical densities at 1:100 dilution prior to rVSVΔG-EBOV-GP vaccination for
- 509 Ebola vaccine-naïve and heterologous Ebola vaccine-experienced participants, p=0.029. C:
- 510 EBOV GP IgM antibody optical densities at 1:100 dilution for each participant from baseline and
- 511 one, three, and six months post-vaccination. The positive OD threshold is indicated by a dashed
- 512 line D: EBOV GP IgM antibody optical densities at 1:100 dilution at baseline for Ebola vaccine-
- 513 naïve and heterologous Ebola vaccine-experienced participants, p=0.1. ns signifies  $p\geq 0.05$ , \*
- 514 signifies p<0.05.

- 516 Figure 2: Antibody responses to vesicular stomatitis virus Indiana strain matrix protein,
- 517 nucleoprotein, and glycoprotein by ELISA
- 518 Optical densities for each participant from baseline and one, three, and six months post-
- 519 vaccination at 1:100 dilution for A) IgG antibodies to VSV-I matrix protein, B) IgM antibodies
- 520 to VSV-I matrix protein, C) IgG antibodies to VSV-I nucleoprotein, D) IgM antibodies to VSV-I
- 521 nucleoprotein, and E) IgG antibodies to VSV-I glycoprotein. The positive OD threshold is
- 522 indicated by a dashed line and individuals with at least one value exceeding the positivity

| 523 | threshold are shown in red. The VSV-I matrix protein and nucleoprotein are present in the                        |
|-----|--|
| 524 | rVSV $\Delta$ G-EBOV-GP vaccine while the VSV-I glycoprotein is absent from the vaccine.                         |
| 525 |  |
| 526 | Figure 3: Representative IgG-producing memory B cell ELISpots at baseline and 6 months post-                     |
| 527 | rVSV∆G-EBOV-GP vaccination   |
| 528 | A: A representative ELISpot from an Ebola vaccine-naïve participant demonstrating a new IgG-                     |
| 529 | producing memory B cell (MBC) response at six months post-vaccination to EBOV GP only. B:                        |
| 530 | A representative ELISpot from a heterologous Ebola vaccine-experienced participant with IgG-                     |
| 531 | producing MBC responses to EBOV GP both at baseline and six months post-rVSV $\Delta$ G-EBOV-                    |
| 532 | GP vaccination. C: A representative ELISpot from an Ebola vaccine-naïve participant                              |
| 533 | demonstrating new IgG-producing MBC responses at six months post-vaccination to EBOV GP,                         |
| 534 | VSV-I M protein, and VSV-I NP.   |
| 535 |  |
| 536 | Figure 4: Intracellular cytokine staining for IFN- $\gamma$ , IL-2, and TNF- $\alpha$ from CD4+ and CD8+ T       |
| 537 | cells  |
| 538 | Peripheral blood mononuclear cells from vaccinees at baseline and one month following                            |
| 539 | rVSV $\Delta$ G-EBOV-GP vaccination were assessed for production of IFN- $\gamma$ , IL-2, and TNF- $\alpha$ from |
| 540 | CD4+ or CD8+ T cells by intracellular cytokine staining using pooled peptides spanning the                       |
| 541 | entire Zaire ebolavirus glycoprotein (A, B), VSV-I matrix protein (C, D), or VSV-I                               |
| 542 | nucleoprotein (E,F). ns signifies p≥0.05, * signifies p<0.05, ** signifies p<0.001.                              |
| 543 |  |

- 544 Figure 5: Fold change in Ebola IgG antibody optical densities at 1 month compared to baseline
- 545 according the detectability of T cells recognizing VSV-I M (A) or NP (B) peptide pools at
- 546 baseline. Median values with 95% intervals are shown.

547

- 548 Figure 6: Pie charts representing the functionality of CD4+ or CD8+ T cells at one month post-
- 549 rVSVAG-EBOV-GP vaccination in response to peptides from Zaire ebolavirus glycoprotein,
- 550 VSV-I matrix protein, or VSV-I nucleoprotein.
- 551 Pie charts representing the mean functionality of CD4+ T cells (A, C, E, G) and CD8+ T cells
- 552 (B, D, F, H) at one month following rVSVAG-EBOV-GP vaccination to EBOV GP for Ebola
- 553 vaccine-naïve (A, B, n=21) or Ebola vaccine-experienced (C, D, n=11) participants, and to VSV-
- 554 I matrix protein (E,F, n=32) and VSV-I NP (G, H, n=32) among all participants. Due to
- rounding, the total mean percentage of cells of each functionality may not add up precisely to
- 556 100%.

| 558 | Acknowledgements: We also wish to acknowledge the main study team at the NIH Clinical         |
|-----|---|
| 559 | Center and at the University of Minnesota Data Center under whose auspices the PREPARE trial  |
| 560 | has been conducted. We would also like to thank our study participants for their volunteerism |
| 561 | and acknowledge the important contributions of the following Emory Hope Clinic staff          |
| 562 | members: Dawn Battle, Mary Bower, Justin Colwell, Rijalda Deovic, Tamera Franks, Tigisty      |
| 563 | Girmay, Mari Hart, Christopher Huerta, Hannah Huston, Sara Jo Johnson, Brandi Johnson, Dean   |
| 564 | Kleinhenz, Pam Lankford-Turner, Hollie Macenczak, Regina Mosley, Eileen Osinski, Michele      |
| 565 | McCullough, Divyanshu Raheja, Brittany Robinson, Sirajud-Deen Talib and Juton Winston.        |


#### 567 **References:**

- 568 [1] Centers for Disease Control and Prevention. 2014-2016 Ebola Outbreak in West Africa.569 2019.
- 570 [2] World Health Organization. 10th Ebola outbreak in the Democratic Republic of the Congo
- 571 declared over; vigilance against flare-ups and support for survivors must continue. 2020.
- 572 [3] European Medicines Agency. Ebola. 2019.
- 573 [4] Merck Sharp & Dohme Corp. ERVEBO®(Ebola Zaire Vaccine, Live) Suspension for
- 574 intramuscular injection [package insert]. US Food and Drug Administration Website
- 575 <u>https://wwwfdagov/media/133748/download</u> Accessed 1 July 2021.
- 576 [5] World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola
- 577 vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic
- 578 Republic of the Congo: an example of integration of research into epidemic response. 2019.
- 579 [6] Dahlke C, Kasonta R, Lunemann S, Krahling V, Zinser ME, Biedenkopf N, et al. Dose-
- 580 dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
- 581 EBioMedicine. 2017;19:107-18.
- 582 [7] Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, et al. Antibodies
- 583 are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in
- nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893-8.
- 585 [8] Antonello J, Grant-Klein RJ, Nichols R, Kennedy SB, Dubey S, Simon JK. Serostatus cutoff
- 586 levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus Zaire
- 587 Ebola virus envelope glycoprotein vaccine: An evidence-based analysis. Vaccine. 2020;38:4885-
- 588 91.


| 589 | [9] Menicucci AR, Sureshchandra S, Marzi A, Feldmann H, Messaoudi I. Transcriptomic             |
|-----|---|
| 590 | analysis reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated             |
| 591 | protection. Sci Rep. 2017;7:919.  |
| 592 | [10] Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy          |
| 593 | assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind,          |
| 594 | randomised, placebo-controlled, test-of-concept trial. Lancet (London, England). 2008;372:1881- |
| 595 | 93.   |
| 596 | [11] Auclair S, Liu F, Niu Q, Hou W, Churchyard G, Morgan C, et al. Distinct susceptibility of  |
| 597 | HIV vaccine vector-induced CD4 T cells to HIV infection. PLoS Pathog. 2018;14:e1006888-e.       |
| 598 | [12] Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human            |
| 599 | adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1     |
| 600 | vaccine. J Clin Invest. 2012;122:359-67.  |
|     |   |


- 601 [13] Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5
- 602 immune complexes creates an improved environment for replication of HIV in T cells. J Exp
- 603 Med. 2008;205:2717-25.
- 604 [14] Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis
- 605 viruses as vaccine vectors. Journal of virology. 1999;73:3723-32.
- 606 [15] Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D. Vesicular stomatitis virus-
- based vaccines against Lassa and Ebola viruses. Emerg Infect Dis. 2015;21:305-7.
- 608 [16] Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rechtien A, et al. Detectable
- 609 Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following
- 610 VSV-Ebola Virus Vaccination in Humans. J Infect Dis. 2019;219:556-61.


- 611 [17] Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, et al. A Recombinant
- 612 Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017;376:330-41.
- 613 [18] Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT, Jr., Beigel JH. Human
- 614 antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing
- 615 IgM antibodies. Nat Med. 2016;22:1439-47.
- 616 [19] Koch T, Rottstegge M, Ruibal P, Gomez-Medina S, Nelson EV, Escudero-Pérez B, et al.
- 617 Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite
- 618 Similar Levels of Circulating Immunoglobulins. Viruses. 2020;12.
- 619 [20] Davis C, Tipton T, Sabir S, Aitken C, Bennett S, Becker S, et al. Postexposure Prophylaxis
- 620 With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the
- 621 United Kingdom: An Operational, Safety, and Immunogenicity Report. Clin Infect Dis.
- 622 2020;71:2872-9.
- 623 [21] Puddington L, Bevan MJ, Rose JK, Lefrancois L. N protein is the predominant antigen
- recognized by vesicular stomatitis virus-specific cytotoxic T cells. J Virol. 1986;60:708-17.
- 625 [22] Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, et al. Circulating
- 626 follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-
- 627 ZEBOV Ebola vaccine. Scientific reports. 2016;6:27944-.
- 628 [23] Hardgrave KL, Neas BR, Scofield RH, Harley JB. Antibodies to vesicular stomatitis virus
- 629 proteins in patients with systemic lupus erythematosus and in normal subjects. Arthritis Rheum.
- 630 1993;36:962-70.




Α VSV-I Matrix Protein IgG Antibodies






























**Baseline VSV-I M T Cell Status** 


. Щ<sub>1</sub>.



В

**Baseline VSV-I NP T Cell Status** 

Α



3.7%